Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.40 -1.4%	$1.15	$0.69 ▼ $3.94	$281.44M	0.82	4.95 million shs	2.63 million shs
IGMS IGM Biosciences	$1.31 +3.1%	$1.26	$0.92 ▼ $22.50	$76.35M	0.6	545,486 shs	487,358 shs
IVA Inventiva	$3.22 -3.9%	$3.28	$1.53 ▼ $4.05	$319.99M	0.73	17,937 shs	7,649 shs
VOR Vor Biopharma	$2.10 +1.4%	$1.22	$0.13 ▼ $3.29	$262.42M	2.04	8.21 million shs	2.45 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	-1.41%	-7.28%	+21.74%	+28.44%	-39.39%
IGMS IGM Biosciences	+3.15%	+3.15%	-0.76%	-2.96%	-88.26%
IVA Inventiva	-2.72%	+2.74%	+8.05%	-4.73%	+40.61%
VOR Vor Biopharma	+1.45%	-4.55%	+44.83%	+217.51%	+126.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.0284 of 5 stars	3.4	3.0	3.9	2.4	1.7	0.6
IGMS IGM Biosciences	4.2114 of 5 stars	3.0	3.0	4.6	2.7	3.3	0.6
IVA Inventiva	2.2215 of 5 stars	3.4	3.0	0.0	1.1	1.7	0.6
VOR Vor Biopharma	3.2875 of 5 stars	4.3	0.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	400.00% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	319.85% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	222.98% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	168.03% Upside

Current Analyst Ratings Breakdown

Latest IGMS, IVA, VOR, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$7.00 ➝ $0.40
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.84	$0.02 per share	59.10	($1.97) per share	-0.71
IGMS IGM Biosciences	$2.68M	29.39	N/A	N/A	$0.82 per share	1.60
IVA Inventiva	$9.95M	30.96	N/A	N/A	($1.21) per share	-2.66
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/5/2025 (Estimated)
IGMS IGM Biosciences	-$195.79M	-$3.27	N/A	N/A	N/A	-36.81%	-125.30%	-20.61%	8/13/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IGMS, IVA, VOR, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	IGMS IGM Biosciences	-$0.12	N/A	N/A	N/A	$0.40 million	N/A
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	N/A	N/A	N/A	$62.55 million	N/A
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
IGMS IGM Biosciences	N/A	5.71	5.71
IVA Inventiva	N/A	0.92	0.92
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
IGMS IGM Biosciences	42.79%
IVA Inventiva	19.06%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
IGMS IGM Biosciences	57.00%
IVA Inventiva	32.00%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
IGMS IGM Biosciences	190	60.12 million	25.85 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

IGMS, IVA, VOR, and ESPR Headlines

Recent News About These Companies

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $5.63

August 2 at 2:21 AM | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30 at 2:57 AM | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30 at 2:45 AM | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

Vor Biopharma Announces Key Leadership Changes

July 25, 2025 | theglobeandmail.com

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop

July 23, 2025 | finance.yahoo.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025 | globenewswire.com

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

July 20, 2025 | msn.com

Vor Bio Grants Stock Options and RSUs to New Chief Development Officer Dr. Qing Zuraw

July 18, 2025 | quiverquant.comQ

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | globenewswire.com

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

July 17, 2025 | globenewswire.com

Vor Biopharma Names Sandy Mahatme Chief Financial Officer

July 11, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 11, 2025 | finanznachrichten.de

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10, 2025 | globenewswire.com

Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants

July 8, 2025 | seekingalpha.com

Biopharma layoffs for first half of the year jump 32% YOY

July 8, 2025 | fiercebiotech.comF

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

July 8, 2025 | marketbeat.com

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6, 2025 | ft.com

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Vor Biopharma Q2 EPS Estimate Decreased by HC Wainwright

July 2, 2025 | marketbeat.com

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?
By Nathan Reiff | July 22, 2025
View D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?
This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out
By Thomas Hughes | July 16, 2025
View This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out
Cameco's 80% 3-Month Gain May Be Just the Start
By Jeffrey Neal Johnson | July 17, 2025
View Cameco's 80% 3-Month Gain May Be Just the Start
3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite
By Nathan Reiff | July 22, 2025
View 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite

IGMS, IVA, VOR, and ESPR Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.40 -0.02 (-1.41%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.40 0.00 (0.00%)

As of 08/1/2025 07:54 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

IGM Biosciences NASDAQ:IGMS

$1.31 +0.04 (+3.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.28 -0.03 (-2.29%)

As of 08/1/2025 05:16 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Inventiva NASDAQ:IVA

$3.28 -0.07 (-2.09%)

As of 08/1/2025 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Vor Biopharma NYSE:VOR

$2.10 +0.03 (+1.45%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.04 -0.06 (-2.86%)

As of 08/1/2025 07:37 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time